Creatine Won’t Fight Inflammation For Most People, Study Finds

Millions of Americans take creatine hoping it will do more than build muscle. Some believe it fights inflammation, the kind tied to chronic disease, aging, and joint pain. But a new scientific review says that hope is largely misplaced.

Researchers pooled data from eight randomized, double-blind, placebo-controlled trials to find out whether creatine meaningfully reduces inflammatory markers. Across those trials, which included older adults and people with knee arthritis, creatine did not show a reliable effect on common long-term inflammation markers. One notable exception emerged: elite endurance athletes pushing their bodies to extreme limits.

That matters because chronic, low-grade inflammation, a state where the immune system stays partially activated over time, is tied to heart disease, type 2 diabetes, joint breakdown, and the muscle loss that comes with aging. If creatine could reliably dial that down, it would be a meaningful public health tool. According to this review, published in Frontiers in Immunology, it generally cannot.

Eight Trials Put Creatine’s Anti-Inflammatory Claims to the Test

To get a broader picture than any single trial could provide, the research team conducted a systematic review and meta-analysis, combining results from multiple individual studies. Researchers searched seven major medical databases for studies published through December 2025, starting with 789 records. After removing duplicates and screening for quality, eight studies qualified.

Eligible studies had to involve real human participants, whether healthy individuals, athletes, or patients with medical conditions, compared against a placebo group. Studies using multi-ingredient supplements were excluded since creatine’s independent effect could not be isolated. Researchers tracked two well-established blood markers of inflammation: C-reactive protein, or CRP, a protein the liver produces during inflammation, and interleukin-6, or IL-6, a signaling molecule released by the immune system.

Participants ranged from young trained male athletes in their mid-twenties to older adults in their late sixties and seventies. One study enrolled patients with mild to moderate knee arthritis. Another involved chronic hemodialysis patients, though that trial did not drive the main CRP and IL-6 conclusions. Creatine doses ranged from 2 to 20 grams per day, and supplementation length stretched from five days to six months.

Across Most Groups, Creatine Left Inflammation Unchanged

When researchers pooled the CRP data, they found no statistically meaningful effect from creatine, whether looking at short-term or long-term use. For long-term supplementation, results were remarkably consistent across trials, with essentially zero variation between studies. IL-6 measured over months of supplementation showed the same pattern.

Two studies examined creatine’s effects on CRP after a single bout of intense exercise, drawing on 61 participants. Again, no meaningful benefit appeared. One study showed virtually no effect; the other showed a non-significant result that numerically favored the placebo group.

Studies that did show benefit painted a very specific picture. In one trial with 34 male distance runners, five days of creatine loading before a 30-kilometer race reduced post-race increases in two inflammatory molecules: tumor necrosis factor-alpha, a key immune signaling protein, and prostaglandin E2, a compound involved in pain and inflammation. In another trial with 11 male triathletes competing in a half-Ironman event, a similar five-day protocol reduced levels of those same molecules plus a third inflammatory marker. Both trials involved extreme endurance events far outside what most people encounter in daily life.

By contrast, a 12-week creatine trial in 18 patients with knee arthritis found zero effect on five inflammation markers. A 12-week trial in 27 older adults pairing creatine with resistance training found no differences versus placebo. A six-month trial in 39 older adults using the same combination produced no meaningful changes in CRP or IL-6.

Why Creatine May Only Help Under Extreme Conditions

Researchers offer a biological explanation. Creatine appears to protect muscle cells during intense exercise by increasing the water content inside those cells, possibly making membranes more resistant to mechanical trauma and reducing the release of cellular debris that triggers inflammation. Under extreme endurance stress, that protection seems to translate into measurably lower inflammatory responses.

Chronic, low-grade inflammation operates through entirely different pathways, driven by factors like excess body fat, immune system aging, and metabolic dysfunction. Creatine does not appear equipped to address any of those root causes, which likely explains why it consistently came up short in older adults and arthritis patients regardless of how long they took it.

Creatine Appeared Well Tolerated in These Small Trials

Across the included trials, creatine was generally well tolerated, with no serious adverse effects reported, whether participants were young athletes on high doses for five days or older adults on lower doses for six months. One long-term study in older adults noted a modest increase in blood creatinine, a byproduct the kidneys filter out, but kidney function itself remained normal.

For the millions of people taking creatine hoping to get ahead of chronic inflammation, the evidence isn’t there yet. Running a triathlon might be a different story, but the gym, the medicine cabinet, and the aging process appear to be on their own.

---

Disclaimer: This article is not intended to serve as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a physician or other qualified health provider with any questions about a medical condition.

---